Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Glioblastoma Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program (GBMRP) to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on Service Members and their Families, Veterans and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The GBMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 GBMRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY24 GBMRP must address one or more of the following Focus Areas, not all of which will be applicable to every mechanism:
Hypothesis Development Award:
Biomarkers:
Identification and development of promising biomarkers for glioblastoma. Biomarkers may include, but are not limited to, susceptibility/risk, diagnostic or prognostic, monitoring/disease progression, predictive, therapeutic response, or safety biomarkers. Noninvasive or minimally invasive strategies and technologies are encouraged.
Drug Delivery:
Strategies and technologies for increased therapeutic efficacy and reduced toxicity including chemical, molecular, or mechanical delivery approaches with consideration of overcoming the blood-brain barrier and increasing access to the central nervous system.
Resource Development Award:
Models
Enhanced development, characterization, and validation of novel disease models that accurately recapitulate glioblastoma pathobiology, particularly the immune component and disease recurrence or progression.
Award Mechanism
Eligibility
Key Mechanism Elements
Funding
Hypothesis Development Award
Investigators at all academic levels (or equivalent)
Supports initial exploration of innovative and potentially groundbreaking concepts in glioblastoma research that may lead to promising new products, devices, clinical guidance, or emerging technologies for patient care.
Preliminary data not required; however, applicant must provide scientific rationale to support the feasibility of the research.
Submissions must address one of the FY24 focus areas of:
Biomarkers
Drug delivery
Partnering PI Option allows two or more Principal Investigators (PIs), termed Initiating and Partnering PIs, to collaborate on a single application.
Clinical trials are not allowed.
Submission of a Letter of Intent is required prior to full application submission.
Single PI Option:
Maximum funding of $200,000 for direct costs (plus indirect costs).
Maximum period of performance is 2 years
Partnering PI Option:
Maximum funding of $300,000 for direct costs (plus indirect costs)
Maximum period of performance is 2 years
Resource Development Award
Investigators at all academic levels (or equivalent)
Supports product-driven research aimed at developing tools for use by the research and/or clinical communities.
Emphasis on post proof-of-concept studies focused on continued development, characterization, and validation of novel glioblastoma disease models.
Preliminary data is required.
Clinical trials are not allowed.
Submission of a Letter of Intent is required prior to full application submission.
Maximum funding of $500,000 for direct costs (plus indirect costs)
Maximum period of performance is 3 years
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the GBMRP or other CDMRP-administered programs, please visit the CDMRP website(https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs 301-619-9783 usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil
The world's first gene-based cancer therapy, immunotherapy—or CAR T cell therapy—is being heralded as a game-changer in the treatment of aggressive cancers like glioblastoma.
The Glioblastoma Research Organization's Project Rush is in collaboration with Lenox Hill Hospital's Department of Neurosurgery's Brain Tumor Center in New York City.
The office of the Congressionally Directed Medical Research Programs (CDMRP) manages Congressional Special Interest Medical Research Programs (CSI) encompassing breast, prostate, and ovarian cancers, neurofibromatosis, military health, and other specified areas.
Our sustained advocacy efforts to increase NIH funding, and brain tumor funding specifically, has led to the agency now estimating it will fund $456 million in brain cancer research in FY 2024.
Introduction: My name is Lakeisha Bayer VM, I am a brainy, kind, enchanting, healthy, lovely, clean, witty person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
